A61K 38/225
Calcitonin gene related peptide
Official title: {Calcitonin gene related peptide}
A61K38/225 (Calcitonin gene related peptide) appears on 96 US grants and 91 published applications in this corpus.
Search patents in A61K- Granted patents
- 96
- Published applications
- 91
- Assignees
- 64
- Inventors
- 149
- Latest grant
- 2 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 3 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 6 | 0 |
| 1998 | 0 | 0 |
| 1999 | 10 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 2 |
| 2002 | 2 | 1 |
| 2003 | 3 | 1 |
| 2004 | 0 | 2 |
| 2005 | 1 | 4 |
| 2006 | 2 | 7 |
| 2007 | 1 | 3 |
| 2008 | 0 | 8 |
| 2009 | 5 | 2 |
| 2010 | 5 | 3 |
| 2011 | 2 | 5 |
| 2012 | 5 | 2 |
| 2013 | 7 | 6 |
| 2014 | 2 | 6 |
| 2015 | 4 | 3 |
| 2016 | 3 | 2 |
| 2017 | 4 | 8 |
| 2018 | 1 | 0 |
| 2019 | 3 | 2 |
| 2020 | 2 | 7 |
| 2021 | 1 | 6 |
| 2022 | 4 | 5 |
| 2023 | 2 | 4 |
| 2024 | 1 | 2 |
| 2025 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Degradable multi-arm polyethylene glycol derivative2 Sep 2025US 12,404,367 B2Nof Corporation
- Compounds for use in inducing myocardial perfusion recovery6 Feb 2024US 11,890,324 B2Epoqe Pharma ApS
- Systems and methods for the treatment of symptoms associated with migraines24 Oct 2023US 11,793,472 B2Welt Corp., Ltd.
- Dosing and use of long-acting CLR/ramp agonists18 Jul 2023US 11,701,409 B2Adepthera LLC
- Methods of treating inflammatory skin disorders6 Dec 2022US 11,517,612 B2Nepsone Ehf
- Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of NOS2, NOS3, VIP, KCNMA1, and CGRP genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-NOS2, or Escherichia coli strain SCS110-AF/VTvaf17-NOS3, or Escherichia coli strain SCS110-AF/VTvaf17-VIP, or Escherichia coli strain SCS110-AF/VTvaf17-KCNMA1, or Escherichia coli strain SCS110-AF/V7 Nov 2024US 2024/0366787 A1Cell and Gene Therapy Ltd
- Compounds for use in inducing myocardial perfusion recovery13 Jun 2024US 2024/0189393 A1Epoqe Pharma ApS
- Methods, devices, and systems for treating lens protein aggregation diseases5 Oct 2023US 2023/0310380 A1
- Methods, devices, and systems for treating lens protein aggregation diseases5 Oct 2023US 2023/0310471 A1
- Methods of treating inflammatory skin disorders15 Jun 2023US 2023/0181693 A1Nepsone Ehf
Most cited
By later US patents
- Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers310US 5,702,717 AMacroMed, Inc. · 1997
- Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions198US 7,048,906 B2Cedars-Sinai Medical Center · 2006
- Delayed drug-releasing microspheres151US 5,993,855 AShiseido Company, Ltd. · 1999
- Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia135US 6,558,708 B1Cedars-Sinai Medical Center · 2003
- Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin115US 6,019,967 ASociete L' Oreal S.A. · 2000